向METTL3诱导ER+乳腺癌细胞中的代谢脆弱性
Mary H Sumlut1,2, Jing Feng3,4, Xiang Zhang2,3,4
1Departments of Biochemistry and Molecular Genetics, University of Louisville, Louisville, Kentucky, USA.
Endocrine-related cancer
|November 26, 2025
概括
在内分泌敏感和耐药乳腺癌中,METTL3抑制对癌细胞代谢产生不同的影响. 使用STM2457准METTL3,使用CB-839准GLS1显示出耐药ER+乳腺癌治疗的前景.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 代谢研究研究 代谢研究
背景情况:
- 像N6-甲基氨酸 (m6A) 这样的表皮转录体标记调节基因表达,并与癌症有关.
- 作为m6A编写酶的METTL3,在各种癌症中影响瘤促进活动和代谢途径,包括雌激素受体阳性乳腺癌 (ER+BC).
- 在METTL3抑制后对内分泌敏感或耐药ER+BC亚型的代谢变化仍未得到充分研究.
研究的目的:
- 通过使用STM2457在内分泌敏感和耐药ER+BC细胞中研究药理METTL3抑制的代谢效应.
- 分析ER+BC亚型中对METTL3抑制的反应中的差异性代谢重编程.
- 评估组合治疗中将METTL3抑制与GLS1抑制相结合的潜力.
主要方法:
- 在ER+BC细胞系 (MCF-7,ZR-75-1,LCC9,ZR-75-1-4-OHT) 中用STM2457进行METTL3的药理抑制.
- 评估细胞代谢,包括糖解和线粒体活动.
- 同位素追踪通过三碳酸 (TCA) 循环量化葡萄糖氧化.
- 对谷氨胺吸收,谷氨胺分解和相关酶/载体的表达的分析 (GLS1,ASCT2).
- 使用STM2457和GLS1抑制剂CB-839.9的组合疗法研究.
主要成果:
- 在耐药ER+BC细胞中,STM2457选择性地降低了糖解活性,并在LCC9细胞中改变了hexokinase 2表达.
- 抑制METTL3抑制了线粒体活性,并在MCF-7和LCC9细胞中减少了TCA循环葡萄糖氧化.
- 观察到谷氨胺吸收和谷氨胺分解的增加,特别是在内分泌抵抗性LCC9细胞中,在MCF-7细胞中有差异性GLS1拼接变体,ASCT2载体表达的增加.
- 与CB-839的联合治疗增强了STM2457的疗效,特别是在内分泌抵抗细胞系 (LCC9和ZR-75-1-4-OHT) 中.
结论:
- 抑制METTL3会在内分泌敏感和耐药ER+BC细胞中诱导明显的糖分和氧化代谢转移.
- 这些代谢变化给ER+BC带来了潜在的治疗漏洞.
- 结合METTL3和GLS1的向表明了治疗潜力,特别是对于内分泌抵抗性乳腺癌亚型.
相关概念视频
02:57Targeted Cancer Therapies
8.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
8.6K
02:38Mitogens and the Cell Cycle
7.7K
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
7.7K
03:03mTOR Signaling and Cancer Progression
4.6K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
4.6K
02:30Metastasis
6.3K
Metastasis is the spread of cancer cells from the original site to distant locations in the body. Cancer cells can spread via blood vessels (hematogenous) as well as lymph vessels in the body.
Epithelial-to-Mesenchymal Transition
The epithelial-to-mesenchymal transition or EMT is a developmental process commonly observed in wound healing, embryogenesis, and cancer metastasis. EMT is induced by transforming growth factor-beta (TGF-β) or receptor tyrosine kinase (RTK) ligands, which further...
Epithelial-to-Mesenchymal Transition
The epithelial-to-mesenchymal transition or EMT is a developmental process commonly observed in wound healing, embryogenesis, and cancer metastasis. EMT is induced by transforming growth factor-beta (TGF-β) or receptor tyrosine kinase (RTK) ligands, which further...
6.3K